How Hormone Changes Affect Irritability and Brain Activity in Teen Girls With Depression
Tests whether steadying hormones with a contraceptive pill changes irritability in depressed teen girls.
Plain-language title generated from the registry record
Registry title: Teen Vulnerability to Irritability: Brain and Estrogen Changes
Key facts
- Where
- Chapel Hill, United StatesSee the 2 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 16 years old?
Source: NCT07544966, who can take part
Where in United States
- Biomedical Research Imaging Center (BRIC) at UNCChapel Hill, United StatesNo longer taking part
- Carolina CrossingChapel Hill, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of North Carolina, Chapel Hill
- Trial code
- NCT07544966
- Record updated
- 24 August 2026
- Original description
Purpose: Risk of severe psychopathology increases dramatically during adolescence, especially for females. Changes in ovarian steroids across the menstrual cycle produce windows of vulnerability to mood disturbances, particularly during the abrupt withdrawal of estradiol (E2) and progesterone (P4) prior to menses onset. Irrefutable evidence links stress with affective symptoms, potentially mediated by E2-related modifications of frontolimbic connectivity and prefrontal gamma-aminobutyric acid (GABA) inhibitory signaling. The primary objective of this project is to empirically test the impact of E2 and P4 change on vulnerable brain networks associated with irritability and other depressive symptoms in female adolescents at risk of suicide.Read full original descriptionShow less
Neurobiological Mechanisms of Susceptibility to Estradiol Fluctuation in Female Adolescents at Risk of Suicide: An Experimental Approach
Purpose: Risk of severe psychopathology increases dramatically during adolescence, especially for females. Changes in ovarian steroids across the menstrual cycle produce windows of vulnerability to mood disturbances, particularly during the abrupt withdrawal of estradiol (E2) and progesterone (P4) prior to menses onset. Irrefutable evidence links stress with affective symptoms, potentially mediated by E2-related modifications of frontolimbic connectivity and prefrontal gamma-aminobutyric acid (GABA) inhibitory signaling. The primary objective of this project is to empirically test the impact of E2 and P4 change on vulnerable brain networks associated with irritability and other depressive symptoms in female adolescents at risk of suicide.
Participants: The investigators will enroll 50 female adolescents ages 12-16 who are at risk of suicide (i.e., moderate depressive symptoms), and are eligible to receive oral contraceptives and undergo MRI imaging.
Procedure: Using a randomized, placebo-controlled, cross-over design, participants will be studied under two conditions: 8 weeks of E2 and P4 stabilization (continuous combined oral contraceptive (COC) to prevent perimenstrual withdrawal) and 8 weeks of placebo, with a 1-month washout after each condition. Each condition will include: 1) daily samples of E2 and P4 urinary metabolites, 2) daily symptom ratings(e.g., irritability, negative affect and suicidal thoughts and behaviors (STBs)), and 3) a neuroimaging session with MRI and magnetic resonance spectroscopy (MRS).
Inclusion: Assigned female sex at birth; Between the ages of 12 and 16; Be eligible to receive a low-dose oral contraceptive (COC); Post-menarche. Participants will be post-menarche to avoid potential OC-related effects on bone growth prior to menarche; At risk of suicide. To be considered "at suicide risk" participants must meet the following-Mood and Feelings Questionnaire score of ≥ 27.
Exclusion: Personal history of metabolic or autoimmune disease; Epilepsy; Cardiovascular, gastrointestinal, hepatic, renal, or pulmonary disease Diabetes mellitus with vascular disease; Uncontrolled hypertension; Liver tumors (benign or malignant) or liver disease; Undiagnosed abnormal uterine bleeding; Current or past deep vein thrombosis or pulmonary embolism; Cerebrovascular disease Coronary artery disease; Thrombogenic valvular or rhythm disease (e.g., subacute bacterial endocarditis with valvular disease, atrial fibrillation); Current or history of breast cancer or other hormone-sensitive malignancy; Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir; Personal or first-degree relative with breast cancer or thromboembolic events; Endometriosis; Headaches with focal neurological symptoms or migraine with aura; Known or suspected pregnancy; Inherited or acquired hypercoagulopathies.